The Institute for International Research will be holding its 9th annual "Generic Drugs Summit," June 18-20 in Washington, D.C.

According to IIR, this is "the leading independent forum addressing business and legal concerns impacting the generics marketplace.  This event attracts 200+ senior-level professionals representing government, regulatory and legal affairs as well as marketing, sales and business development."

The agenda on June 19-20 includes many interesting presentations:

• "Update on Hatch-Waxman Reform," by none other than Rep. Henry A. Waxman
• "Removing Hurdles that Slow Affordable Generics from Coming to Market," by Sen. Debbie A. Stabenow
• "The Future of Biogenerics and Other Measures to Reduce Healthcare Costs," by Rep. Frank Pallone, Jr.
• "Federal Trade Commission Actions Involving Generic Drugs," by Phil Eisenstat, Sr. Attorney, FTC
• "Patent Reform: A Generic Industry Friend or Foe?"
• "The Changing Competitive Landscape of the Generic Drugs Industry"
• "Understanding the 180-Day Forfeiture Provisions of the MMA" (I'll be presenting this topic)
• "Trends in New Pharmaceutical Patent Claim Strategies"

In addition, the Generic Drugs Summit features two pre-conference workshops on June 18: "Strategies for Filing Successful Paragraph IV Certifications" and "Understanding How to Submit Quality ANDAs Based on QbR to Reduce Approval Time."